Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Cash from Investing Activities: 2014-2024

Historic Cash from Investing Activities for Protagonist Therapeutics (PTGX) over the last 11 years, with Dec 2024 value amounting to -$299.5 million.

  • Protagonist Therapeutics' Cash from Investing Activities rose 71.94% to -$58.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$106.9 million, marking a year-over-year increase of 69.64%. This contributed to the annual value of -$299.5 million for FY2024, which is 662.86% down from last year.
  • Protagonist Therapeutics' Cash from Investing Activities amounted to -$299.5 million in FY2024, which was down 662.86% from -$39.3 million recorded in FY2023.
  • In the past 5 years, Protagonist Therapeutics' Cash from Investing Activities ranged from a high of $91.5 million in FY2022 and a low of -$299.5 million during FY2024.
  • For the 3-year period, Protagonist Therapeutics' Cash from Investing Activities averaged around -$82.4 million, with its median value being -$39.3 million (2023).
  • As far as peak fluctuations go, Protagonist Therapeutics' Cash from Investing Activities spiked by 676.72% in 2022, and later crashed by 662.86% in 2024.
  • Over the past 5 years, Protagonist Therapeutics' Cash from Investing Activities (Yearly) stood at -$91.0 million in 2020, then skyrocketed by 82.56% to -$15.9 million in 2021, then spiked by 676.72% to $91.5 million in 2022, then plummeted by 142.92% to -$39.3 million in 2023, then tumbled by 662.86% to -$299.5 million in 2024.